Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pralsetinib DDI Study in RET-Altered Solid Tumors
NCT07704658Phase 4Recruiting
- Sponsor
- Rigel Pharmaceuticals, Inc.
- Start
- Mar 2026
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
A Phase 4 trial of pralsetinib in solid tumor, sponsored by Rigel Pharmaceuticals, Inc.. Started Mar 2026; status: recruiting.
02
Drugs
pralsetinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07704658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07704658.